Tuberculosis–Cancer Parallels in Immune Response Regulation
<i>Mycobacterium tuberculosis</i> and cancer are two diseases with proclivity for the development of resistance to the host immune system. Mechanisms behind resistance can be host derived or disease mediated, but they usually depend on the balance of pro-inflammatory to anti-inflammatory...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/6136 |
| _version_ | 1797555513618071552 |
|---|---|
| author | Thomas E. Bickett Sana D. Karam |
| author_facet | Thomas E. Bickett Sana D. Karam |
| author_sort | Thomas E. Bickett |
| collection | DOAJ |
| description | <i>Mycobacterium tuberculosis</i> and cancer are two diseases with proclivity for the development of resistance to the host immune system. Mechanisms behind resistance can be host derived or disease mediated, but they usually depend on the balance of pro-inflammatory to anti-inflammatory immune signals. Immunotherapies have been the focus of efforts to shift that balance and drive the response required for diseases eradication. The immune response to tuberculosis has widely been thought to be T cell dependent, with the majority of research focused on T cell responses. However, the past decade has seen greater recognition of the importance of the innate immune response, highlighting factors such as trained innate immunity and macrophage polarization to mycobacterial clearance. At the same time, there has been a renaissance of immunotherapy treatments for cancer since the first checkpoint inhibitor passed clinical trials, in addition to work highlighting the importance of innate immune responses to cancer. However, there is still much to learn about host-derived responses and the development of resistance to new cancer therapies. This review examines the similarities between the immune responses to cancer and tuberculosis with the hope that their commonalities will facilitate research collaboration and discovery. |
| first_indexed | 2024-03-10T16:49:35Z |
| format | Article |
| id | doaj.art-340b2238537c4a0ab2ed368488f4b1b9 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:49:35Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-340b2238537c4a0ab2ed368488f4b1b92023-11-20T11:21:41ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-012117613610.3390/ijms21176136Tuberculosis–Cancer Parallels in Immune Response RegulationThomas E. Bickett0Sana D. Karam1Department of Radiation/Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80022, USADepartment of Radiation/Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80022, USA<i>Mycobacterium tuberculosis</i> and cancer are two diseases with proclivity for the development of resistance to the host immune system. Mechanisms behind resistance can be host derived or disease mediated, but they usually depend on the balance of pro-inflammatory to anti-inflammatory immune signals. Immunotherapies have been the focus of efforts to shift that balance and drive the response required for diseases eradication. The immune response to tuberculosis has widely been thought to be T cell dependent, with the majority of research focused on T cell responses. However, the past decade has seen greater recognition of the importance of the innate immune response, highlighting factors such as trained innate immunity and macrophage polarization to mycobacterial clearance. At the same time, there has been a renaissance of immunotherapy treatments for cancer since the first checkpoint inhibitor passed clinical trials, in addition to work highlighting the importance of innate immune responses to cancer. However, there is still much to learn about host-derived responses and the development of resistance to new cancer therapies. This review examines the similarities between the immune responses to cancer and tuberculosis with the hope that their commonalities will facilitate research collaboration and discovery.https://www.mdpi.com/1422-0067/21/17/6136immunotherapy<i>Mycobacterium tuberculosis</i>radiation therapytumor immunology |
| spellingShingle | Thomas E. Bickett Sana D. Karam Tuberculosis–Cancer Parallels in Immune Response Regulation International Journal of Molecular Sciences immunotherapy <i>Mycobacterium tuberculosis</i> radiation therapy tumor immunology |
| title | Tuberculosis–Cancer Parallels in Immune Response Regulation |
| title_full | Tuberculosis–Cancer Parallels in Immune Response Regulation |
| title_fullStr | Tuberculosis–Cancer Parallels in Immune Response Regulation |
| title_full_unstemmed | Tuberculosis–Cancer Parallels in Immune Response Regulation |
| title_short | Tuberculosis–Cancer Parallels in Immune Response Regulation |
| title_sort | tuberculosis cancer parallels in immune response regulation |
| topic | immunotherapy <i>Mycobacterium tuberculosis</i> radiation therapy tumor immunology |
| url | https://www.mdpi.com/1422-0067/21/17/6136 |
| work_keys_str_mv | AT thomasebickett tuberculosiscancerparallelsinimmuneresponseregulation AT sanadkaram tuberculosiscancerparallelsinimmuneresponseregulation |